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Abstract
Background: To analyze the in-hospital complication rate in women suffering from non-ST elevation myocardial 
infarction treated with percutaneous coronary intervention (PCI) compared to men.
Methods: The files of 479 consecutive patients (133 women and 346 men) suffering from a Non STEMI (Non ST-
segment elevation myocardial infarction) between the January 1st 2006 and March 21st 2009 were retrospectively 
analyzed with special attention to every single complication occurring during hospital stay. Data were analyzed using 
nonparametric tests and are reported as median unless otherwise specified. A p value < .05 was considered significant.
Results: As compared to men, women were significantly older (75.8 vs. 65.2 years; p < .005). All cardiovascular risk 
factors but tobacco and hypertension were similar between the groups: men were noticeably more often smoker (p < 
.0001) and women more hypertensive (p < .005). No difference was noticed for pre-hospital cardiovascular drug 
treatment. However women were slightly more severe at entry (more Killip class IV; p = .0023; higher GRACE score for 
in-hospital death - p = .008 and CRUSADE score for bleeding - p < .0001). All the patients underwent PCI of the infarct-
related artery after 24 or 48 hrs post admission without sex-related difference either for timing of PCI or primary success 
rate. During hospitalization, 130 complications were recorded. Though the event rate was slightly higher in women 
(30% vs. 26% - p = NS), no single event was significantly gender related. The logistic regression identified age and CRP 
concentration as the only predictive variables in the whole group. After splitting for genders, these parameters were 
still predictive of events in men. In women however, CRP was the only one with a borderline p value.
Conclusions: Our study does not support any gender difference for in-hospital adverse events in patients treated 
invasively for an acute coronary syndrome without ST-segment elevation and elevated troponin.
Background
Percutaneous Coronary Intervention (PCI) is the pre-
ferred technique for the treatment of acute coronary syn-
drome with or without ST-segment elevation according
to the Guidelines [1]. The available data raise concerns
about sex differences in outcome after invasive treatment
for acute coronary syndromes (ACS). However every day,
PCI is offered to everybody suffering from ACS regard-
less of its gender. In the study reported by Bell et al. in
1993 [2] from a large cohort of 2955 men and 1106
women, a greater in-hospital mortality was recorded in
women and was related, at least partly, to the severity of
the underlying disease rather that gender alone. On the
other hand, no gender related differences in outcome was
found by Mehilli et al [3] after PCI in women and men
who underwent stent placement for stable angina.
Malenka and co-workers [4] analyzed the impact of PCI
techniques improvement on sex difference in outcome
and found no sex specificity in a sample of 33666 patients
of both sex. These authors [4] related their results upon
the improvement in PCI procedures overtime. More
recently, Berger et al [5] analyzed data issued from 11
studies merged in one single database. They reported on
30-day mortality following ACS and found no gender
related difference after adjustment for baseline variables.
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PCI have been reassessed in a report from Duvernoy et al
[6] about a large population of 24,725 patients (31.8%
were women) from 17 hospitals in Michigan between Jan-
uary 2002 and December 2003. PCI was offered in every
case for various clinical presentations. They concluded
that differences in mortality rates between men and
women no longer exist after PCI. They also suggested
that technological advancements have not completely off-
set the relationship between gender and adverse out-
comes after PCI. All these studies included different
clinical presentations of coronary artery disease with a
mixed of ST- segment elevation myocardial infarction,
Non ST-segment elevation myocardial infarction
(NSTEMI), unstable and stable angina, a heterogeneity
which could minimized a difference to some extent. PCI
data about sex related differences are limited in the area
of NSTE-ACS (non ST elevation-acute coronary syn-
drome), a growing subset of coronary artery disease with
an annual incidence of hospital admission of 3 per 1000
inhabitants [1]. Therefore, we aimed to compare the in-
hospital outcome between men and women with
NSTEMI only and treated with PCI.
Methods
Patients and data collection
The files of all consecutive patients admitted to our uni-
versity hospital with the diagnosis of NSTEMI (code
410.7 from ICD-9) between January 1st 2006 and March
21st 2009 was retrospectively analyzed. The diagnosis of
NSTEMI was made according to the classical criteria
enacted by the 2007 Guidelines of the European Society
of Cardiology [1] taking into account clinical data, ECG
changes and raise of cardiac troponin I plasma level.
We collected from the medical files all administrative
data: last name, first name, gender, date of birth, time to
angioplasty, length of stay; the past medical history (car-
diovascular and non cardiovascular); cardiovascular risk
factors: body mass index, diabetes mellitus, hypertension,
dyslipidemia, smoking habits, family history of premature
cardiovascular disease and anxiety. The clinical charac-
teristics (blood pressure, pulse pressure, heart rate, Killip
class) were also noted as well as the biological data
(hemoglobin, hematocrit, platelets count, hemostasis,
higher plasma troponin as a surrogate of infarct size, B-
type natriuretic peptide (BNP) or N Terminal pro-BNP,
plasma glucose at entry, Glycated hemoglobin, CRP (C
reactive protein), plasma creatinine from which glomeru-
lar filtration rate was derived from the Cockcroft formula
[7]; ECG parameters (sinus rhythm or not and ST-T
changes); left ventricular ejection fraction derived from
2-dimensional echocardiography [8] and the PCI proce-
dure reports for the extension of the coronary artery dis-
ease, number of stents and all other procedure related
specificities - e.g. number of coronary arteries treated,
amount of contrast media administered. We also
recorded the number of succeeded or failed procedures
and all reported complications (cardiac, hemorrhagic,
renal, embolic, infectious events) as well as death during
the hospital stay. The appropriate GRACE likelihood for
in-hospital death and complications [9,10] and the CRU-
SADE bleeding score [11] were also entered. The ethical
committee of our institution approved the study design
and data collection.
Statistical analysis
Data are presented as median and inter quartile range,
unless otherwise specified. The normality of the distribu-
tion of all continuous variables was checked using the
D'Agostino and Pearson omnibus normality test. In case
of non normal distribution, continuous data were com-
pared using the Mann and Whitney test in case of
unpaired values and with the Wilcoxon signed rank test
in case of paired data. The time course of some continu-
ous parameters was also assessed using a nonparametric
ANOVA for repeated measures: the Friedman test with
localization of differences by Dunn's multiple comparison
test. Proportions were compared using the Chi-Square
test with Fischer exact test if necessary after. The p value
was considered significant if less than 0.05. The statistical
power was calculated using a 'not significant' chi-square
test comparing two proportions. All statistical analyses
but one were performed using the PRISM package (Prism
4.0c and Statemate for Macintosh; GraphPad software
Inc., USA). Logistic regression was performed with the




The study population consisted in 479 patients, with a
predominance of men (72%). Patients' characteristics are
summarized in Table 1. Women represented 28% of our
sample. They were significantly older (p < 0.005). Among
the cardiovascular risk factors, one can notice that
women were less often smokers (p < 0.0001) and had
more hypertension (p < 0.005). Though diabetes mellitus
was more often reported in men with a borderline p
value, the glycated hemoglobin level was higher in
women (p < 0.03) likely related to a poorer control of
their diabetes. All other reported parameter showed no
gender related difference (Table 1).
Considering the past medical history (Table 2), no dif-
ference was found for the rate of pre-existing cardiovas-
cular disease of any etiology, atrial fibrillation, peripheral
arterial disease and stroke or pacemaker holders. Non-
cardiovascular past history was also similar in both gen-
ders except for chronic obstructive pulmonary disease,
which was significantly more frequent in men (p < 0.04).
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similar whatever the therapeutic class considered: angio-
tensin converting enzyme inhibitors; angiotensin recep-
tor blockers; beta-blockers; antiarrhythmic agents;
calcium channel blockers; lipids lowering agents (statins
and fibrates); antithrombotic agents either antiplatelets
or anticoagulants; diuretics; oral antidiabetic agents also
accounting for metformine; insulin; nitrates. For angio-
tensin system antagonists, beta-blockers and statins, not
only the rate of prescription but also the optimal doses
were similar between genders. The rate of prescription of
antidepressants was however significantly different,
women being more likely to receive this class of drugs
than men (p < 0.03).
Table 1: Demographic data
Men (N = 346) Women (N = 133) p Value
Age (yrs) 65.2 (56.3-75.6) 75.8 (66-80.5) 0.0034
BMI (kg/m2) 27.1 (17-31) 27.1 (17-30) NS
Dyslipemia (%) 36.1 43.6 NS
Total cholesterol (mg/dl) 1.71 (1.39-2.02) 1.65 (1.47-2.14) NS
LDL cholesterol (mg/dl) 1.04 (0.77-1.31) 0.97 (0.7-1.36) NS
HDL cholesterol (mg/dl) 0.4 (0.3-0.43) 0.4 (0.3-.53) NS
Diabetes (%) 34.1 21.0 0.0574
Smoker (%) [current] 70.8 [34.1] 33.1 [18] < .0001
Hypertension 64.7 78 0.0043
Family history (%) 17.1 10.8 NS
Anxiety (%) 2.31 4.60 NS
Abbreviations: BMI: body mass index. Current in brackets stands for active smokers. Family history stands for a family history of premature 
cardiovascular disease. yrs: years.
Table 2: Past history of cardiovascular diseases
Men(N = 346) Women(N = 133) p Value
Non-ischemic heart disease (%) 2.6 11.3 NS
Ischemic heart disease (%) 37 30.8 NS
Left main 1.2 3.8 NS
LAD 27.5 27.1 NS
Circumflex or 1st Marginal 20.8 21.8 NS
Right coronary artery 25.7 19.6 NS
Coronary Artery Bypass Grafting (%) 9.3 6.8 NS
LAD 8.4 4.5 NS
Circumflex or 1st Marginal 1.7 0.8 NS
Right coronary artery 3.8 2.3 NS
Atrial Fibrillation (%) 7.8 8.3 NS
Peripheral Arterial Disease (%)
Lower Limb 17.1 17.3 NS
Carotid 12.7 10.5 NS
Venous thrombo-embolic diseases (%) 3.5 11.3 0.0017
Pace Maker (%) 4.1 3.8 NS
Stroke (%) 8.4 9.8 NS
Abbreviations: LAD: left descending coronary artery.
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The clinical characteristics on admission are described in
Table 3. As compared to men, women had a higher pulse
pressure (68 vs. 60 mm Hg - p < 0.05). Pulse pressure was
slightly but significantly related to age in men (rho = 0.15;
p = 0.008). In women, this wasn't the case (rho = 0.14; p =
0.1 - NS). Moreover, women had also more severe heart
failure. Indeed, 6.5% of women were in Killip class IV and
only 0.9% of men (p < 0.003). This difference could be, at
least partly, related to the higher rate of right heart failure
in women (24% of our female population; p < 0.02). This
trend to a less favorable clinical profile on admission was
also suggested by the probability of in-hospital death
derived from the appropriate GRACE probability (p <
0.01). The likelihood of in-hospital complications accord-
ing to the specific GRACE probability was borderline (p =
0.068). The CRUSADE bleeding likelihood was clearly
higher in women (11%; IQR: 8 - 15 vs. 6%; IQR: 4 - 10 in
men; p < 0.02). In spite of the more compromised hemo-
dynamic profile in women, no difference could be noted
for mean arterial pressure or heart rate between the
groups (Table 3).
ECG changes in anterior leads only were similar in both
groups. ECG changes in all lateral leads were more fre-
quent in women (6.8% vs. 2.3%; p < 0.03) whereas ECG
changes solely in inferior leads were more common in
men (11.8% vs. 5.2%). Most of the patients had combined
ECG changes: 53% of women and 47% of men - p = NS.
One third of the women population and 33.5% of men
had no ECG changes at entry without any statistical dif-
ference. These patients remained in the study on the basis
of clinical presentation and elevation of plasma troponin
I. One atrioventricular block was recorded at entry in
each group. No difference was noted for the presence of
atrial fibrillation on admission (6.1% in men and 7.5% in
women; p = NS). Apart from isolated lateral and inferior
leads concerning a few patients, no difference could be
noted between the groups.
Biological characteristics
The biological characteristics at hospital entry are dis-
played in Table 4. Many classical parameters as well as
Troponin I and BNP plasma level were similar between
genders. Plasma glucose was significantly higher in
women (p < 0.05). Hence, women also had more inflam-
mation as suggested by both CRP (p < 0.05) and plasma
fibrinogen (p < 0.002). In women we noted lower levels of
hemoglobin (p < 0.0001) and of hematocrit (p < 0.0001)
however with the same time course during hospitaliza-
tion in both groups (Figure 1). Baseline renal function
was reduced in women (p < 0.0001).
PCI procedure
All the patients underwent a coronary angiogram with
PCI in a similar median time (Table 5). The contrast
media used was ioxaglic acid in the vast majority of
patients. The remaining was given either iodixanol or
iomeprol. No difference existed between genders for
iodixanol and Iomeprol doses. Men received substantially
more ioxaglic acid (p < 0.02). This apparent excess in con-
trast volume did not translate into renal disorder as
reflected by plasma creatinine and estimated glomerular
filtration rate during hospitalization. Glomerular filtra-
tion rate at the end of hospitalization was 76 ml/min
Table 3: Clinical data at entry
Men (N = 346) Women (N = 133) p Value
Blood pressure (mmHg)
MAP 107 (97-119) 106 (95-120) NS
PP 60 (50-74) 68 (50.5-80) 0.0477
HR (bpm) 75 (64-85) 76 (64-85) NS
Killip class
I (%) 65.5 61.5 NS
II (%) 25.07 22.3 NS
III (%) 8.6 10 NS
IV (%) 0.9 6.15 0.0023
Right heart failure (%) 13.7 23.8 0.0119
GRACE likelihood (In-hospital)
Death (%) 2 (1-6) 3 (1-8) 0.0080
Complications (%) 14 (9-20.0) 16 (10-22.5) 0.0678
CRUSADE likelihood 6 (4-10) 11 (8-15) < 0.02
Abbreviations: bpm: beats per minute. HR: heart rate. MAP: mean arterial pressure. PP: pulse pressure.
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women, not different from baseline values within groups.
The extent of coronary artery disease was similar
between genders. Though there was no sex related differ-
ence for time to PCI and type of procedure, a tendency to
more bare metal stent placement in women was noted
(Table 5). Glycoprotein IIb-IIIa antagonists were used in
22% of men and 20% of women without any difference.
Closure devices were equally used between the groups:
83% of men and 81.5% of women (p = 0.69) (Table 4).
Outcomes
Left ventricular ejection fraction derived from 2-dimen-
sional echocardiography after PCI was near normal and
similar in both groups: 56%; IQR: 47 - 62 in women vs.
55%; IQR: 45 - 60 in men; p = NS). Length of stay was lon-
ger in women (median = 10 days; IQR: 5.5 - 17 vs. 7.5
days; IQR: 5 - 11; p < 0.01).
One hundred and thirty in-hospital complications were
recorded: 90 in men and 40 in women. Thus 30% of
women had experienced at least one complication as
compared to 26% of men (p = NS).
The procedure was unsuccessful in 19 men and 11
women, but the difference was not significant (p = NS).
In-hospital mortality was only 1.9% of the study popula-
tion: 9 patients died (6 men and 3 women; p = NS).
Among men, 1 died from a complete atrioventricular
block, 2 from septic shock, 1 from cardiogenic shock and
2 from stent thrombosis. Among women, 1 died from
severe congestive heart failure, 1 from septic shock and
the last one from per procedure cardiac arrest. The septic
shocks were all related to Staphylococcus Aureus. Nine-
teen patients presented severe hypotension requiring cat-
echolamine support and 16 of them required transfer to
the coronary care unit afterward (10 men vs. 9 women; p
= NS). Two among these 19 collapses were a consequence
of cardiac tamponade. All the others were related to
severe congestive heart failure. The power of the study to
detect a significant change of 0.04 between the groups is
at least 80%.
Sixty-nine patients had a hemorrhagic event: 45 men
and 24 women, p = NS. Most of the hemorrhagic events
were confined to the femoral puncture point without
gender difference: 17 women vs. 30 in men, p = NS. Other
bleedings, including from gastrointestinal tract, were lim-
ited to a few patients (7 women vs. 15 men; p = NS). As a
whole, hemoglobin loss was moderate: median value was
-1.4 mg/dl; IQR = -2.2, -0.7 in women and -1.2 mg/dl;
IQR = -2.1, -0.5 in men; p = NS). Only 39 patients (8% of
the study population) were given blood transfusion with-
Table 4: Biological data at entry
Men (N = 346) Women (N = 133) p Value
Platelets count (n*103/l) 229 (192-278) 252 (201-295) NS
Hemoglobin (g/dl) 14.0 (12.7-15.0) 12.6 (11.3-13.7) 0.0001
Hematocrit (%) 40.8 (37.3-43.3) 37.0 (33.6-40.2) 0.0001
APTT (s) 34 (32-39) 34 (31-39) NS
BNP (ng/l) 104 (46-307) 159 (67-386) NS
eGFR (ml/min) 82 (54-110) 57 (42-81) < 0.0001
Troponin I (μg/l) 1.66 (0.46-6.72) 1.62 (0.47-6.8) NS
Plasma glucose (g/l) 1.24 (1.03-1.69) 1.33 (1.10-2.03) < 0.05
Glycated Hemoglobin (%) 6.1 (5.7-7.1) 6.6 (5.8-7.7) 0.0204
CRP (mg/l) 4.3 (4.0-12.5) 26.7 (7.5-71.0) < 0.05
Fibrinogen (g/l) 3.8 (3.2-4.7) 4.2 (3.2-5.2) < 0.002
Abbreviations: APPT: activated partial thromboplastin time. BNP: B-natriuretic peptide. CRP: C Reactive Protein. eGFR: estimated glomerular 
filtration rate.
Figure 1 Time course of hemoglobin during hospital stay. Com-
pared to baseline, both group as the same course as suggested by a 2-
way ANOVA showing no significant group interaction.  §§§: p < 0.0001 
compared to baseline. ‡‡‡: p < 0.0001 compared to minimal value.  ***: 
p < 0.0001 between women and men.
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the study to detect a significant change of 0.10 between
the groups for bleeding is at least 80%.
We also recorded some other complications figured in
Table 6. These events were observed in 29% of women
and 28% of men. Once more, no difference could be
found between genders.
A logistic regression analysis taking into account sex,
age, CRP, glomerular filtration rate, glycated hemoglobin,
number of coronary vessel disease, pulse pressure,
GRACE scores and CRUSADE score showed that the
only independent predictive parameter was CRP (Chi-2 =
5.873; p = 0.0154). Some of these data were obviously cor-
related with age and sex (GRACE scores, CRUSADE
score and Cockcroft formula). However, we wanted to
include them in a first step in order to stress the strength
of their relationship with the response variable and
choose the best one. Afterward, the parameters remain-
ing in the study were age, CRP, glycated hemoglobin,
number of vessel disease, pulse pressure and sex. After
removing from the model all variables but age, CRP and
sex, because of significance level, we were left with 2 pre-
dictive variables: patients age: (Chi-2 = 13.141; p =
0.0003) and CRP (Chi-2 = 8.989; p = 0.0027) with a poor
deviance goodness of fit as derived from its p-value (Chi-
square = 499.044; p = 0.0212). After Splitting the result
according to genders, this holds true for men: Chi-2 for
age was 12.968 with a p value = 0.0003 and Chi-2 for CRP
was 5.917 and p = 0.015. The deviance became not signif-
icant, suitable with a satisfactory Goodness of fit (devi-
ance = 344.951; p = NS). In women, age was not
significant anymore and CRP was of borderline signifi-
cance (Chi-2: 3.562 and p < 0.06; deviance = 152.62; p =
NS). However, keeping pulse pressure in the final model
resulted in an increased weight for CRP in women: Chi-2
= 4.536 and p < 0.04 without noticeable change in men.
Discussion
Our data showed no difference in outcome between men
and women treated invasively for NSTEMI. The only
parameters that matter are age and inflammation status, a
possible reflection of a more advanced disease state. The
problem of a worse outcome in women undergoing PCI
has been underscored for a long time. In 1993, Bell and
coworkers [2] reported a higher in-hospital and peripro-
cedural mortality in women in a large sample of patients
(n = 4071) after emergency PCI for STEMI, unstable
angina or elective procedure for stable angina. In this
study, genders were similar only for prior myocardial
infarction and number of coronary vessel disease. All
other variables were significantly different. They failed to
find any strong relationship between female gender and
outcome and came to the conclusion that their results
could be more likely related to the severity of the underly-
Table 5: Contrast use, CAD extent and PCI procedures
Men (N = 346) Women (N = 133) p Value
Contrast agents
Ioxaglic acid (ml) 250 (200-340) 211 (180-260) < 0.02
Iodixanol (ml) 220 (171-300) 200 (160-300) NS
Iomeprol (ml) 215 (134-334) 226 (219-350) NS
CAD extent
1-vessel disease (%) 29 34 NS
2-vessel diseases (%) 36 34
3-vessel diseases (%) 35 32
PCI procedure
Time interval to PCI (days) 1 (1-4) 2 (1-4) NS
BMS (%) 51 61 0.052
DES (%) 40 32 NS
Balloon angioplasty (%) 9 14 NS
Thrombus aspiration (%) 1 0 NS
Use of closure devices (%) 83 81.5 NS
Failure (%) 5 8 NS
GPIIb/IIIa antagonists (%) 22 20 NS
Abbreviations: BMS: bare-metal stent. CAD: coronary artery disease. DES: drug eluting stent. GPIIb-IIIa antagonists: Glycoprotein IIb-IIIa 
antagonists. PCI: percutaneous coronary intervention.
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ulation was heterogeneous and could have undermined
their findings. Our data, obtained from a series of homo-
geneous patients are online with their conclusions. There
is no obvious sex related effect per se explaining any dif-
ference in outcome. More recently, Mehilli and others [3]
reported about a series of 1001 women and 3263 men
treated with coronary stenting for symptomatic coronary
artery disease in the nineties on an elective basis. They
did not mention the in-hospital outcome but reported a
higher 30-day event rate in female gender, though this
difference had disappeared at 1 year. They acknowledged
that some heterogeneousness in baseline characteristics
could have explained their findings. Our data emphasize
this aspect. When one can reduce the discrepancies
between genders regarding most of the baseline charac-
teristics, the outcome seems identical. The data reported
by Malenka et al [4] referred to 33,666 patients having
undergone PCI between 1994 and 1999. They had the
basic concept that women were at higher risk for adverse
outcomes after PCI. Though their female patients were
older, had more diabetes, chronic obstructive pulmonary
disease, renal failure, peripheral artery disease and heart
failure, they found no sex related difference for post PCI
coronary bypass grafting or myocardial infarction rate.
They stated that the improvement in PCI techniques
could explain their results. Even in a more contemporary
era, PCI techniques are still improving and we cannot
rule out such a possibility, as we could not analyze this
aspect. However, the progress made during the study
period that could account for our results are unlikely.
There was just a trend to have more women implanted
with bare-metal stents and the rate of drug-eluted stents
was similar between genders. In no way the number of
complications was influenced by the type of stent. The
conclusion we made is also suggested by a recent study
from Berger et al [5] who investigated the relationship
between gender and 30-day mortality in acute coronary
syndromes. The differences they found were largely
explained by differences at presentation and severity of
the coronary artery disease. Weintraub et al. [12] also
reported a higher in-hospital mortality post PCI in
women. However, in the multivariate analysis, the corre-
lates of in-hospital death were by far the severity of the
disease state whereas there was only a trend for female
gender [12]. Welty et al. [13] found no difference between
genders for procedural outcome of PCI and both sex had
a similar success rate in their study. Schuhlen et al. [14]
also found that female gender had no excess risk for
major adverse cardiac events after intracoronary stenting.
Our data confirm that women fared as well as men for
success rate after PCI for NSTEMI. Indeed, failing proce-
dures were low in both groups.
Even though we found no sex related difference for out-
comes, the women we studied were ten years older and
had clearly more hypertension and a trend to lower rate
of diabetes mellitus. They were less likely smokers. These
features are well established not only in coronary artery
disease but also in heart failure [15,16] and reports deal-
ing with gender related differences underlined these
aspects [5]. Therefore, such characteristics don't change
our conclusion. In spite of a lower rate of diabetes melli-
tus, women appeared to have significantly higher plasma
glucose and glycated hemoglobin, likely linked to a
poorer control of their diabetes. Plasma glucose at entry
is predictive of in-hospital mortality as stated by several
studies [17-21]. Hence, the cutoff value of impaired fast-
ing glucose defining the risk for worse outcome has been
specified by Vergès et al. [22] to be above 110 mg/dl. In
our study, we only considered plasma glucose on admis-
Table 6: Complications
Men (N = 346) Women (N = 133) p Value
Death (%) 1.7 2.3 NS
Intensive care unit transfer (%) 2.3 6 0.0832
Counter pulsation intra aortic balloon (%) 1.4 1.5 NS
Collapse (%) 2.9 6.8 0.0662
Acute pulmonary edema (%) 1.5 0.8 NS
Bleeding (%) 13 18 NS
Recurrent ischemia (%) 2.6 1.5 NS
Stent thrombosis (%) 1.5 1.5 NS
Arrhythmia/conduction disturbances (%) 3.8 3 NS
Stroke (%) 0.3 0.8 NS
Infection (%) 6.1 7.6 NS
Allergic reaction (%) 1.2 2.3 NS
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Though statistically different, the gap was weak and could
account for the reported result. Neither plasma glucose at
entry nor glycated hemoglobin remained after the multi-
variate analysis. Our data are corroborated by the paper
from Vivas et al. [23] and from Suleiman et al. [24] who
found that admission plasma glucose had no predictive
value unlike the first fasting plasma glucose that was not
analyzed in our study.
There are several scores for risk prediction at hospital
entry, each of which facilitates patient management with
ACS - GRACE [9], TIMI [25], PURSUIT [26] -. All these
scores have a good predictive value to identify high-risk
subsets of patients who will benefit most from myocar-
dial revascularization performed during initial hospital-
ization [27]. For this study we have chosen the in-hospital
GRACE risk score which is widely used in the setting of
NSTEMI and seems perhaps better than the equivalent
TIMI score [28,29]. We noticed that women had a signifi-
cantly higher GRACE risk score for death and a trend to a
greater likelihood for in-hospital complications. How-
ever, we failed to confirm this difference in the multivari-
ate analysis either for death or for overall complications.
The in-hospital mortality was in agreement with other
reports [24]. Such discrepancy has been stressed in the
literature [24,30]. Indeed, the predictive power of the
GRACE score is well established. Nevertheless, it can be
suboptimal is some cases and might require some recali-
bration as emphasized recently by Elbarouni et al. [31].
We didn't find genders difference for hemorrhagic com-
plications either. The recently reported CRUSADE score
we used [11] has been validated in the NSTEMI setting.
This score takes female gender into account as risk
marker for bleeding and is online with various reported
data. The higher CRUSADE likelihood we found in
women could be related to the weight factor of female
gender in CRUSADE. Another reason for discrepancy
might be linked to the way we analyzed bleeds. In CRU-
SADE, bleeding definition is according to GUSTO
whereas we included all bleeds. We cannot rule out the
effect of the high use of closure device to explain the
recorded data.
We recorded a worse renal function in women, the neg-
ative prognostic value of which has been re-emphasized
recently [32]. These authors [32] concluded from the
large database of the SYNERGY trial, that chronic kidney
disease derived from the estimated glomerular filtration
rate was predictive of 30-day mortality, myocardial
infarction and bleeding. We agree with this claim when
age is not entered in our logistic model. Once this was
done, estimated glomerular filtration rate retained no
more value.
In our patients, we analyzed the inflammation status as
various reports underscored the interest of doing so [33-
36]. Considering the role of inflammation in the initia-
tion, progression and destabilization of atheroma, the
reported result is not surprising. Our data on CRP and
prediction of complications including death in NSTEMI
patients are in harmony with other results summarized
by Blake and Ridker [35] and others [37,38].
Study Limitation
We studied a sample of NSTEMI according to the avail-
able guidelines. However, the sample size is small though
comparable to others. Our study is from one site and
included only 28% of female gender and was of retrospec-
tive nature. Though we do believe that female gender is
not at higher risk for PCI in NSTEMI, more data are
needed to draw final conclusion.
Conclusions
In spite of a higher risk profile in female as stated by vari-
ous well-established parameters, female patients treated
with PCI for Non STEMI have the same in-hospital
course outcome than men. The only predictive variables
for adverse events were age and inflammation status.
This latter could be the expression of the stage of the
underlying pathological process at least to some extent.
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